JPRN-UMIN000023483已完成未知
Efficacy and safety of PCSK9 inhibitor for dyslipidemia - EVOLUTION trial (effects of EVOLocUmab on lipid and oxidaTIve stress biOmarkers in high-risk patieNts with Cardiovascular disease)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Doctor's decision not to register to this regimen
研究者
相似试验
已完成
不适用
egacy Effects of PCSK9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaqueacute coronary syndromeJPRN-UMIN000041925Gifu Heart Center7
已完成
4 期
Modelling the impact of PCSK9 inhibitors on lipoproteins in patients with dyslipidemiaE78.5Hyperlipidaemia, unspecifiedDRKS00011663niversitätsklinikum Freiburg30
已完成
不适用
PCSK9 Inhibitor Usage on Target Vessel Dysfunction in patients with hypercholesterolemia after coronary stenting, a Multicenter Randomized Controlled TrialhypercholesterolemiaHypercholesterolemia after coronary stentingJPRN-jRCTs071200032Matoba Tetsuya42
招募中
不适用
Impact of PCSK9 Inhibitor on the Characteristics of Lipid-rich Coronary Plaques Assessed by Near-infrared SpectroscopyIschemic Heart DiseaseJPRN-UMIN000040318Gifu Heart Center50
招募中
不适用
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®Hypercholesterolemia, FamilialNCT04313270Federico II University25